Drug intelligence / Profile preview

aurimodi

Development stage: Unknown
Lead developer: Nanjing Chang'ao Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Aurimodi (YF-49-92.MLS) is an orally bioavailable small molecule inhibitor of decaprenylphosphoryl-beta-D-ribose 2'-epimerase (DprE1), an essential enzyme involved in the biosynthesis of the mycobacterial cell wall component arabinogalactan. Developed by Nanjing Chang'ao Pharmaceutical Technology, Aurimodi is designed to treat various forms of pulmonary tuberculosis, including drug-sensitive, multidrug-resistant (MDR), and extensively drug-resistant (XDR) strains. By inhibiting DprE1, the drug prevents the conversion of decaprenylphosphoryl-ribose (DPR) to decaprenylphosphoryl-arabinose (DPA), a critical precursor for cell wall assembly, thereby exerting potent bactericidal activity against *Mycobacterium tuberculosis*. It has advanced into Phase 2 clinical trials to evaluate its early bactericidal activity and safety in patients.

Other names: Aurimodi

Targets

DprE1 (Decaprenylphosphoryl-beta-D-ribose oxidase)

Beyond the preview

Go deeper on aurimodi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aurimodi.

Explore the full profile